Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study

BACKGROUND: Fingolimod was the first oral therapy approved for treating relapsing-remitting multiple sclerosis (RRMS) in 2010. This open-label study evaluated the safety and efficacy of fingolide(R), 0.5 mg in Iranian MS patients during one-year follow-up. METHODS: A multicenter, open-label, longitu...

Descripción completa

Detalles Bibliográficos
Autores principales: Doosti, Rozita, Naser Moghadasi, Abdorreza, Azimi, Amir Reza, Karbalai Saleh, Shahrokh, Etemadifar, Masoud, Shaygannejad, Vahid, Ashtari, Fereshteh, Harirchian, Mohammad Hossein, Siroos, Seyed Bahaadin, Ayramloo, Hormoz, Majdinasab, Nastaran, Hojjati, Seyyed Mohammad Masood, Asghari, Nabiollah, Baghbanian, Seyed Mohammad, Cheraghmakani, Hamed, Abedini, Mahmoud, Sedighi, Behnaz, Mohseni Abbas abadi, Negar, Ghasemitabar, Maedeh, Talebianpour, Sara, Babayi Daylari, Tohid, Dana, Vahid, Ghaleh noie, Neda, Sahraian, Mohammad Ali
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Babol University of Medical Sciences 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223042/
https://www.ncbi.nlm.nih.gov/pubmed/34221275
http://dx.doi.org/10.22088/cjim.12.3.263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8223042/
https://www.ncbi.nlm.nih.gov/pubmed/34221275
http://dx.doi.org/10.22088/cjim.12.3.263

Ejemplares similares